Login / Signup

A Clinical Framework for Evaluating Cannabis Product Quality and Safety.

Caroline A MacCallumLindsay A LoCarly A PistawkaMichael Boivin
Published in: Cannabis and cannabinoid research (2022)
Increase in medical cannabis use, along with available products, warrants the need for clinicians to be knowledgeable in evaluating the quality of any cannabis product presented in clinical practice. Determining whether a product is regulated within the region is key in assessing overall quality and safety. Regulated products are held to a higher standard including independent testing, contamination mitigation, and concentration limits. Here, we present a clinical framework in evaluating cannabis products to ascertain the quality and regulation level of the product. Evaluation includes assessing the source company, reviewing product details (e.g., type, cannabinoid content, and labeling), and assessing quality control variables such as manufacturing and decontamination processes. The quality of products patients use is an important part of mitigating cannabis-related harms, especially in medically vulnerable patients. Currently, there is a great need to implement widespread standardization and regulations to ensure product quality and safety.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • clinical practice
  • quality improvement
  • quality control
  • healthcare
  • palliative care
  • drinking water
  • heavy metals
  • human health
  • drug induced